All In MedTech

Device Trial Radar · NCT04298177

Personalized Atrial Fibrillation Ablation With QDOT

Personalized Atrial Fibrillation Ablation With the QDOT Catheter - The QDOT-by-LAW Trial

Last checked: Nov 20, 2026Latest source record: Aug 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

77

Planned (sponsor's estimate)

Start

Mar 1, 2022

Primary completion

Dec 1, 2022

Study completion Dec 30, 2023

Sponsor

Lead sponsor
Antonio Berruezo, MD, PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 6, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Circumferential pulmonary vein isolation (PVI) has become a mainstay in the treatment of atrial fibrillation (AF), particularly in symptomatic patients with paroxysmal AF (PAF) intolerant or refractory to medical treatment. The safety and short-term performance of the novel QDOT® catheter (Biosense Webster, Irvine, CA, USA), that allows for a high-power short-duration (HPSD) ablation, has already been evaluated in the QDOT-FAST clinical study, with favorable data on feasibility and safety, and lowered fluoroscopy and procedure times needed to achieve complete PVI. HPSD ablation was based on immediate heat formation during the resistive phase, affecting a small tissue depth at 90 W/4 s (irrigation at 8 ml/min) with a temperature limit of 65ºC. However, up to date there are no randomized studies evaluating the real usefulness of the QDOT® catheter. Longer-term follow-up is still required to verify the long-term effectiveness and correlations between short-term follow-up and arrhythmia recurrence when using this catheter. The impact of this novel catheter, when used in conjunction with a personalized ablation protocol that uses the information of left atrial wall thickness (LAWT) to modulate the AI target at each ablation point, compared with a standard ablation protocol following the published CLOSE study criteria is already unknown.

Conditions

  • Atrial Fibrillation

Interventions

  • Atrial fibrillation ablation using the QDOT® catheterDevice

    Atrial fibrillation ablation will be performed using the QDOT® catheter. The ablation mode will be selected according to the MDCT-derived LAWT information.

  • Standard atrial fibrillation ablationProcedure

    Atrial fibrillation ablation will be performed using the SmartTouch® catheter. The ablation parameters will be adjusted according to the settings previously described in the CLOSE study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical efficacyTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Teknon Medical Center

    Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.